Therefore, a series of dual blockade approaches targeting LAG-3 and PD-1 is currently undergoing clinical evaluation as a potential treatment option for advanced breast cancer (NCT03742349 and NCT03005782), and double antibodies are under evaluation. This evidence concerns the gene LAG3 and breast carcinoma.